Ficlatuzumab plus chemotherapy effective in relapsed or refractory acute myeloid leukemia

ficlatuzumab plus chemotherapy effective in relapsed or refractory acute myeloid leukemia

Sumary of Ficlatuzumab plus chemotherapy effective in relapsed or refractory acute myeloid leukemia:

  • Back to Healio Ficlatuzumab plus single-agent chemotherapy showed encouraging efficacy and appeared safe among patients with relapsed or refractory acute myeloid leukemia, according to phase 1 study results published in Blood Cancer Discovery.
  • Blaser, MD, PhD, assistant professor of leukemia research at The Ohio State University Comprehensive Cancer Center, told Healio.
  • Blaser and colleagues assessed the safety and efficacy of a four-dose regimen of 20 mg/kg ficlatuzumab given 14 days apart in combination with high-dose cytarabine in a cohort of 17 patients (median age, 58 years;
  • Secondary objectives included the rate of complete remission, PFS and OS. Researchers assessed response through next-generation sequencing with the ARUP Myeloid Malignancies Mutation panel and minimal residual disease using the University of Washington multiparameter flow cytometry assay.
  • Results showed the ficlatuzumab-chemotherapy combination induced an overall response rate of 53%, with all responders experiencing complete remission and four having no signs of minimal residual disease.
  • Eight responders and two nonresponders underwent hematopoietic stem cell transplantation, of whom six remained in remission at last follow-up.
  • Researchers additionally examined peripheral blood mononuclear cells pooled at baseline and at various other timepoints during the study.
  • ” Ficlatuzumab could be a treatment option for patients with relapsed or refractory AML if larger randomized studies confirm its efficacy, according to Bradley.

Want to know more click here go to source.

From -

Close
Generic selectors
Exact matches only
Search in title
Search in content

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close